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Recurrence or persistence of clinical signs is a frequent problem and certainly the most common 
reason for referral of a diabetic cat. The first step is to confirm that the cat is indeed poorly regulated, 
i.e. has clinical signs of diabetes. High blood glucose levels may be incorrectly interpreted to be the 
result of poor glycemic control when in fact they are stress induced. Fructosamine concentration is 
also not always a reliable parameter and is sometimes moderately to markedly increased, although 
the cat is clinically well. A stepwise approach is helpful to define the reason for the problem.
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1. Technical problems 
Errors in handling and injecting insulin are frequent and include incorrect mixing, diluting, freezing or 
heating of insulin, use of outdated insulin, drawing up air, inappropriate insulin dose and timing, poor 
injection technique and use of the wrong size of syringe (U-40/ml vs. U-100/ml; frequent error!). 
Careful history taking and watching the owner during the procedure will unravel the problem.  
2. Insulin underdose 
Most cats are well controlled with insulin doses < 1U /kg BID. If the insulin dose is considerably less 
than 1 U/kg BID and underdose is a potential reason for poor glycemic control, then a stepwise 
increase up to 1 U/kg BID is recommended. We usually increase in steps of 0.5 U/cat BID 
approximately every 5 days.  
3. Rule out insulin overdose and the Somogyi effect 
The Somogyi effect is defined as rebound hyperglycemia due to hypersecretion of counter-regulatory 
hormones (mainly epinephrine, glucagon) during hypoglycemia. The latter in turn is induced by a 
(slight) overdose of insulin. Owners may report that days of good glycemic control are followed by 
several days of poor control, which should always raise the suspicion of the Somogyi effect. Diagnosis 
requires the documentation of hypoglycemia or a very rapid drop in blood glucose concentration 
followed by hyperglycemia (blood glucose usually > 17 mmol/l, 300 mg/dl) within a 12-hour period. To 
identify the problem, a series of BGCs may be needed, which may be best performed by home-
monitoring.  
4. Rule out short duration of insulin effect 
Short duration is particularly common when NPH insulins are used and also occurs in some cats 
treated with Lente-type insulin (Caninsulin®). As a result pronounced hyperglycemia (> 15 mmol/l, 270 
mg/dl) is present for several hours throughout the day. Diagnosis requires generation of BGCs, single 
glucose measurements (e.g. measurement only once in the morning) may lead to the erroneous 
assumption of insulin underdose.   
5. Prolonged duration of insulin effect  
Problems with prolonged duration of insulin effect are usually not seen with NPH or Lente-type insulin. 
It may, however, occur in some cats treated with twice daily application of PZI or Insulin Glargine. If 
duration of effect is longer than 12 hours, an overlap in insulin action results, which eventually leads to 
the Somogyi effect or to overt hypoglycemia. Indications for a prolonged duration of effect are a 
glucose nadir occurring 10 or more hours after insulin administration and constantly decreasing 
glucose concentrations beyond the time of the next insulin administration.  
6. Impaired absorption of insulin 
Slow absorption was a frequent problem with Ultralente insulin, which is no longer available. This 
problem is not considered to be important in the classes of insulins currently used.  
7. Binding of insulin by insulin antibodies 
Because the amino acid sequence of feline insulin differs to a varying extent from human, porcine and 
bovine insulin, it is logical to assume that treatment will result in the production of anti-insulin 
antibodies. The relevance of anti-insulin antibodies in the management of diabetic cats has not been 
extensively investigated. Two studies identified antibodies in 14% and 37% of cats treated with 
recombinant human, beef and beef/pork insulins. There was no correlation between glycemic control 
and the presence or absence of antibodies.
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 Those findings allow the assumption that problems in 
regulating diabetic cats are only rarely (if at all) due to anti-insulin antibodies.  
8. Concurrent disorders causing insulin resistance 
No insulin dose clearly defines insulin resistance. It has been suggested that insulin resistance should 
be suspected when glycemic control is poor despite insulin doses of > 1.5 U/kg BID, high doses (> 1.5 
U/kg) are required to maintain blood glucose < 17 mmol/l (300 mg/dl) and when glycemic control is 
erratic and the insulin dose must be constantly adjusted.
5
 Any inflammatory, infectious, neoplastic and 
endocrine disorder can cause insulin resistance, as well as obesity and drugs such as glucocorticoids 
and progestagens. In cats, insulin resistance is most commonly caused by severe obesity, chronic 
renal failure, chronic pancreatitis, stomatitis/oral infections, hypercortisolism and hypersomatotropism 
(acromegaly). The latter two diseases have the potential of causing the most severe insulin resistance. 
Hypercortisolism is considered to be rare: 75 – 80% of cats have pituitary-dependent disease and 20 – 
25% have cortisol-secreting adrenocortical tumors. In addition to pu/pd and weight loss, which are 
usually due to concurrent diabetes mellitus, typical clinical signs are abdominal enlargement, an 
unkempt seborrheic hair coat, thinning of the hair coat, failure of hair to regrow or alopecia and muscle 
weakness. Severe cases may have thin fragile skin that tears easily. Cats with large pituitary masses 
may have CNS disturbances. However, clinical signs may also be mild and hypercortisolism is often 
not suspected until it becomes evident that the diabetes is difficult to regulate. The dexamethasone 
test and the urine corticoid-to-creatinine ratio are the preferred screening tests. Hypersomatotropism in 
cats is caused by a growth hormone (GH)-producing tumor in the pars distalis of the pituitary gland. 
GH has catabolic and anabolic effects; the latter are in part mediated by insulin-like growth factor-1. 
The catabolic effects are mainly due to insulin antagonism and are the reason for the diabetes 
mellitus. The anabolic effects include proliferation of bone, cartilage, soft tissue and organs resulting in 
a large body size, broad head and large paws, weight gain, prognathia inferior, respiratory difficulties 
because of thickening of pharyngeal tissues, degenerative arthopathy and organomegaly with 
potential organ dysfunction. Acromegaly has long been considered a rare disorder. However, it was 
recently suggested that acromegaly occurs more frequently than previously thought and is most likely 
underdiagnosed.
6
 Since the availability of a validated GH assay for cats is a problem, diagnosis is 
usually based on the finding of high IGF-1 concentration. Two important points should be kept in mind. 
First, circulating IGF-1 is bound to proteins, which must be removed before measurement. However, 
not all methods are equally effective, and intra-assay inference of binding proteins may lead to false 
high IGF-1 levels. Therefore, only assays validated for the cat should be used. Second, IGF-1 
concentrations are often low in newly diagnosed diabetic cats and increase markedly after initiating 
insulin therapy. Low IGF-1 levels have also been seen initially in untreated diabetic cats with 
acromegaly. This observation is explained by the fact that relatively high insulin concentrations are 
required in the portal vein for the expression and function of GH receptors on hepatocytes, and this 
mechanism is impaired in insulin-deficient states.
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In the majority of poorly regulated diabeteic cats it is possible to define the underlying problem by a 
careful work-up. 
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